Baxter partners to bring at-home dialysis to more patients

Nephrons captured with a 63X objective on a Nikon Confocal A1R microscope--Courtesy of Nils Lindstrom et al CC-BY 4.0

Baxter is teaming up with dialysis care provider Satellite Healthcare to make advanced care available to more patients in the U.S.

Announced Friday, the four-year deal will see Satellite Healthcare providing Baxter’s automated peritoneal dialysis system to patients and integrate the company’s high-flux dialyzer into its hemodialysis offerings, according to a statement. Satellite provides dialysis at traditional dialysis centers, and also has home dialysis centers where patients are trained to perform their treatments at home. Other details were not disclosed.

The AMIA Automated Peritoneal Dialysis system has patient-focused features to facilitate home dialysis, such as voice guidance. It includes Baxter’s cloud-based telemedicine platform, Sharesource, through which clinicians can monitor and manage their home dialysis patients, according to the company. Baxter’s Revaclear high-flux dialyzer consists of a three-layer polyarylethersulfone membrane and is indicated for the treatment of chronic and acute renal failure.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

Satellite also launched Re-Imagine Home, a push to raise awareness of home dialysis and to increase its home dialysis patient population from 20% to 40%. “AMIA, Baxter’s new technology, is a foundational tool for Satellite Healthcare in reaching our Re-Imagine Home goal to make home dialysis an accessible and effective modality option for more dialysis patients,” said Satellite CEO Rick Barnett, in the statement.

Home dialysis is also a priority for Baxter since it spun off its therapeutics-based Baxalta last year. In May, CEO José Almeida noted that only 13% of dialysis patients are treated at home, but that number should be at least 40%.

- here's the statement

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.

GlaxoSmithKline is teaming up with CRISPR-focused outfit Mammoth Biosciences to develop a fast, handheld and disposable COVID-19 test.